Last reviewed · How we verify
infliximab+azathioprine
Infliximab blocks TNF-α to reduce inflammation while azathioprine suppresses immune cell proliferation, providing dual immunosuppression for inflammatory bowel disease.
Infliximab blocks TNF-α to reduce inflammation while azathioprine suppresses immune cell proliferation, providing dual immunosuppression for inflammatory bowel disease. Used for Moderate to severe Crohn's disease, Moderate to severe ulcerative colitis.
At a glance
| Generic name | infliximab+azathioprine |
|---|---|
| Also known as | remicade/imuran |
| Sponsor | Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW |
| Drug class | TNF-α inhibitor + immunosuppressant combination |
| Target | TNF-α receptor (infliximab); purine metabolism (azathioprine) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Infliximab is a TNF-α inhibitor monoclonal antibody that neutralizes tumor necrosis factor-alpha, a key pro-inflammatory cytokine in IBD pathogenesis. Azathioprine is a purine analog that inhibits T-cell and B-cell proliferation. The combination provides synergistic immunosuppression to induce and maintain remission in inflammatory bowel disease.
Approved indications
- Moderate to severe Crohn's disease
- Moderate to severe ulcerative colitis
Common side effects
- Infections (bacterial, viral, fungal)
- Infusion reactions
- Nausea and vomiting
- Myelosuppression
- Hepatotoxicity
- Pancreatitis
Key clinical trials
- Combined Immunosuppression for Pediatric Crohn's Disease (PHASE4)
- The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children (NA)
- An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis (PHASE2)
- Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis (PHASE3)
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: